StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Remicade (infliximab by Quarter

Remicade (infliximab — immunology, legacy ex-U.S. marketing rights) — U.S. sales ($M) ($M)

QuarterlyAnnual

Merck Remicade (infliximab: $0M in Q4 2025. That is the highest of the 36 quarters on record here.

Latest, Q4 2025
0
Period ended Dec 31, 2025
Change on a year earlier
–
0 in Q4 2024
History
36 quarters
Since Q1 2017
Sources
31
Documents cited below

Where the Q4 2025 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2026-02-24) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedRemicade (infliximab — immunology, legacy ex-U.S. marketing rights) — U.S. sales ($M) ($M)Year on yearSource
Q4 2025Dec 31, 20250–Form 10-K (filed 2026-02-24) ↗
Q3 2025Sep 30, 20250–Form 10-Q (filed 2025-11-05) ↗
Q2 2025Jun 30, 20250–Form 10-Q (filed 2025-08-05) ↗
Q1 2025Mar 31, 20250–Form 10-Q (filed 2025-05-02) ↗
Q4 2024Dec 31, 20240–Form 10-K (filed 2026-02-24) ↗
Q3 2024Sep 30, 20240–Form 10-Q (filed 2025-11-05) ↗
Q2 2024Jun 30, 20240–Form 10-Q (filed 2025-08-05) ↗
Q1 2024Mar 31, 20240–Form 10-Q (filed 2025-05-02) ↗
Q4 2023Dec 31, 20230–Form 10-K (filed 2026-02-24) ↗
Q3 2023Sep 30, 20230–Form 10-Q (filed 2024-11-06) ↗
Q2 2023Jun 30, 20230–Form 10-Q (filed 2024-08-05) ↗
Q1 2023Mar 31, 20230–Form 10-Q (filed 2024-05-03) ↗
Q4 2022Dec 31, 20220–Form 10-K (filed 2025-02-25) ↗
Q3 2022Sep 30, 20220–Form 10-Q (filed 2023-11-03) ↗
Q2 2022Jun 30, 20220–Form 10-Q (filed 2023-08-07) ↗
Q1 2022Mar 31, 20220–Form 10-Q (filed 2023-05-05) ↗

Cite this data

StockData. (2026). Merck Remicade (infliximab ($M), quarterly Q1 2017–Q4 2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-remicade-us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.